Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 4,777 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Cancers Clear all
Completed Phase 2 Interventional

Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors

NCT00618969
View directory record Official record
Conditions
Hematologic Neoplasms, Anemia, Aplastic, Hemoglobinuria, Paroxysmal, Multiple Myeloma
Interventions
haploidentical allogeneic PBSC transp
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 31, 2026, 5:00 AM EDT
Active, not recruiting Not applicable Interventional

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

NCT05703269
View directory record Official record
Conditions
NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma, Brain Metastases, Adult, Non-small Cell Lung Cancer, SCLC, Small-cell Lung Cancer
Interventions
single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
34
States / cities
Savannah, Georgia • Decatur, Illinois • Effingham, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 5:00 AM EDT
Active, not recruiting Phase 2 Interventional

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06991556
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
JSB462, Abiraterone, Enzalutamide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
21
States / cities
La Jolla, California • Santa Monica, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 5:00 AM EDT
Terminated Not applicable Interventional

Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies

NCT00514722
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Lymphoma, Large-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, T-Cell, Peripheral, T-NK Cell Lymphoma, Hodgkin Disease
Interventions
umbilical cord stem cells
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 31, 2026, 5:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

NCT05394831
View directory record Official record
Conditions
EGFR Mutant Advanced Non-small Cell Lung Cancer
Interventions
JIN-A02
Drug
Lead sponsor
J Ints Bio
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 31, 2026, 5:00 AM EDT
Active, not recruiting No phase listed Observational

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

NCT05064553
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Interventions
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Device · Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
76
States / cities
Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 31, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

NCT02654639
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
TAS-102, Bevacizumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 31, 2026, 5:00 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

aPBI Re-irradiation

NCT07612254
View directory record Official record
Conditions
Breast Cancer Recurrent
Interventions
Reirradiation
Radiation
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT02254551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
LDE225, Bortezomib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Denver, Colorado • Cincinnati, Ohio • Chattanooga, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 31, 2026, 5:00 AM EDT
Terminated No phase listed Observational

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

NCT01109407
View directory record Official record
Conditions
Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Not applicable Interventional

A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema

NCT04908254
View directory record Official record
Conditions
Lymphedema, Lymphedema of Upper Arm, Lymphedema, Breast Cancer
Interventions
Crossover Device (PCD or Dayspring - alternate to first group)
Device
Lead sponsor
Koya Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Los Altos, California • Morgan Hill, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 31, 2026, 5:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945
View directory record Official record
Conditions
Multiple Myeloma
Interventions
AZD0305, Elranatamab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety Study in Patients With Chronic Lymphocytic Leukemia

NCT00283101
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic
Interventions
SGN-40 (anti-huCD40 mAb)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

NCT06547112
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Motixafortide, G-CSF
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 78 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 31, 2026, 5:00 AM EDT
Recruiting Phase 2 Interventional

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
158
States / cities
Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

NCT03416153
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Carboplatin, Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 31, 2026, 5:00 AM EDT
Completed No phase listed Observational

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

NCT05447637
View directory record Official record
Conditions
Prostate Cancer
Interventions
Invitae multi-cancer gene panel
Diagnostic Test
Lead sponsor
Invitae Corporation
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
San Diego, California • San Francisco, California • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 2 Interventional

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

NCT00201695
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Doxil®, Vincristine, Dexamethasone, Arsenic Trioxide
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 31, 2026, 5:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

RASopathy Biorepository

NCT04395495
View directory record Official record
Conditions
RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2065
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

NCT00927875
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
BMS-833923, Carboplatin, Etoposide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions
BGT226
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

NCT01432600
View directory record Official record
Conditions
Myeloma
Interventions
Pomalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
San Francisco, California • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 31, 2026, 5:00 AM EDT
Completed Phase 1Phase 2 Interventional

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

NCT00005851
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, laboratory biomarker analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Aurora, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 31, 2026, 5:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

NCT01342172
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Lenalidomide
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 31, 2026, 5:00 AM EDT